Analyst Price Target is $7.06
▲ +242.82% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Greenbrook TMS in the last 3 months. The average price target is $7.06, with a high forecast of $11.00 and a low forecast of $4.50. The average price target represents a 242.82% upside from the last price of $2.06.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Greenbrook TMS.
Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services. As of December 31, 2021, the company operated 94 wholly owned and 55 TMS centers in the commonwealth of Virginia and the States of Maryland, Delaware, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, Michigan, Alaska, Oregon, California, Iowa, and Massachusetts. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.